Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Roche and Genentech's latest AI collaborator raises $25M Series A to reinvent one of the oldest cancer targets
5 years ago
AI
2020 report cards continue rolling in, with analysts detailing record-breaking fundraising for the UK
5 years ago
Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology
5 years ago
Cell/Gene Tx
Illumina co-founder Mark Chee moves from the genome to the proteome with upstart Encodia
5 years ago
One of the most ambitious startup teams in biotech just outlined plans for a $400M IPO and a valuation of about $4B
5 years ago
Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy
5 years ago
Startups
As targeted therapies get ever more precise, Deerfield unveils $50M bet on a Harvard professor's chemistry insights
5 years ago
Startups
Ex-MD Anderson chief DePinho is helping launch another biotech — and he's sticking with familiar ground
5 years ago
Harvard spinout kicks off 2021 with a crossover round and sights set on the clinic
5 years ago
Plexium adds industry vet Mike Grey to the brain trust with new investor cash funding its protein degradation play
5 years ago
The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq
5 years ago
The IPO queue adds 5 more biotechs hoping to ring in 2021 by blitzing Nasdaq
5 years ago
'Bluest of blue-chip investors' pump $94M into Sekar Kathiresan's quest to bring CRISPR to the heart
5 years ago
Cell/Gene Tx
An ambitious GV-backed gene editing upstart re-emerges as a one-drug kidney company
5 years ago
Startups
A cardiovascular cell therapy player grabs $54M for a new beginning — where next-gen CAR-T approach features prominently
5 years ago
Eli Lilly re-ups diversity pledge, pitching in $30M to venture fund for minority-owned healthcare firms
5 years ago
Pharma
With its rank-and-file churning out startups, Dana-Farber launches venture fund to capitalize on that success
5 years ago
As venture funding in oncology flourishes, neuro has seen shallower pockets. A European investor wants to change that
5 years ago
Fujifilm doubles down on Boston foothold, renting some major legroom to chase cell and gene therapies
5 years ago
Manufacturing
Chris Garabedian's first Xontogeny company, Landos Biopharma, preps a nine-figure IPO as lead program heads to PhIII
5 years ago
Painting by the numbers, Sana founders carve up a giant unicorn-sized IPO — for a biotech that hasn't quite made it to the clinic
5 years ago
Pfizer's investment fund is making waves in VC — including a $25M bet on IBD player Vedanta Biosciences
5 years ago
IDO on the rebound? Danish outfit IO Biotech hopes so with oversubscribed Series B one month after BTD in melanoma
5 years ago
With a torrent of venture cash gushing from a global pack of unicorn hunters, this biotech founder vows to stay hungry
5 years ago
First page
Previous page
84
85
86
87
88
89
90
Next page
Last page